Jiugiang Bio disclosed its semi-annual report for 2026, with total operating revenue of 679 million yuan in the first half, up 1.55% year-on-year, and net profit attributable to the parent of 210 million yuan, up 20.02% year-on-year. The company plans to distribute a cash dividend of 1.5 yuan per 10 shares, tax included, to all shareholders. During the reporting period, non-GAAP net profit was 206 million yuan, up 18.86% year-on-year, net cash flow from operating activities was 247 million yuan, up 1.11% year-on-year, basic earnings per share was 0.36 yuan, and weighted average return on equity was 5.59%. The company is mainly engaged in the production and sales of in vitro diagnostic reagents and instruments.
Beijing Strong Biotechnologies IncJiugiang Bio's net profit up 20.02% and dividend plan announced.
